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is similar for males and females. Growing inequality generally increases GMS cover-
age but pushes some persons aged over 70 above the qualifying income threshold. 
Repeating 2010 average income in 2011 would increase the 2011 GMS medicines 
cost by around € 110m; repeating the 2010 inequality changes would increase it by 
a further € 105m, ceteris paribus. ConClusions: Fiscal cutbacks during recession 
induce countervailing increases in the medical card population and the public cost 
of its medicines. These are the first systematic and detailed estimates – by age, 
gender and region – of whose medical access is affected and how much the offset-
ting public cost will increase.
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objeCtives: About 52.6% or 125,434 people of the population in Burgenland is 
physical inactive. As a risk factor for several chronic diseases like cardiovascular 
diseases, type 2 diabetes, osteoporosis, depression, back-pain, hypertension, breast 
cancer and colorectal carcinoma physical inactivity can potentially be a substantial 
public health burden. Furthermore, it is one of the greatest risk factors for global 
mortality. Hence, the aim of the analysis was to estimate the direct health-care costs 
saved, the number of diseases and premature death saved each year attributable to 
a health promotion program focusing on walking (“3,000 steps” more). Methods: 
The evaluation of the health-economic impact was performed using a cost-of-illness 
analysis. We have used relative risk (RR) estimates from the literature to evaluate 
the effects of physical inactivity on the above mentioned diseases. Afterwards, the 
population-attributable fraction (PAF) for each illness to estimate the risk factor on 
the given disease was computed. Direct medical costs were considered from the 
health care system perspective. Costs were calculated bottom-up for the year 2012. 
We have calculated effects of a reduction in inactivity level by 10,000 physical inac-
tive people in Burgenland. Results: Results show that physical inactivity causes 
27,542 cases of illness as well as 50 premature deaths in population of Burgenland, 
leading to a total cost-of-illness of 58.9 million Euro (6.3% of total health expendi-
ture). Reducing the inactive group by 10,000 people, 2,221 cases of illness and cases 
of death will be reduced by four. Moreover the cost of illness could be reduced by 
6.40 million Euro each year of which 5.03 million Euro are directly related to dimin-
ish physical inactivity. ConClusions: Physical inactivity represents an important 
public health burden in Austria. Even modest reductions in inactivity levels could 
result in substantial cost savings.
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objeCtives: The modified reference price procedure, which was introduced 
in October 2011, caused significant savings in the Health Insurance Fund’s 
Pharmaceutical budget. In our analysis we aim to give an insight into the effects 
of this measure on the drug consumption and on the sales of the pharmaceutical 
companies as well as measure the generated savings and losses on the side of the 
industry. In the course of the analysis we examine the change in the demand of 
the related drugs and in their composition, from the aspect of industry, financer 
and patients. We explore which are the price strategies of the companies and are 
they managed to increase the sales or decrease the losses with them. The proper 
knowledge of the effects of blind bid will support the decision making of the con-
cerned market actors as well as the further rulemaking. Methods: A retrospec-
tive data analysis was conducted on the official NHIFA (national Health Insurance 
Fund) monthly data-base between October 2011 and March 2013. Results: In 
the blind bid procedure 90 companies, 169 active substances and more than 2100 
product were involved. The relevant products market share is almost 30% of the 
total Hungarian Pharmaceutical budget, which is almost 1 billion € annually. 
As we found, the blind bid process has a significant saving effect for the 
financer. The cumulative savings on the 18 months period reached 113 millions 
€ for the financer. It means 24% reduction on the average reimbursement level, 
whilst the average manufacturer price decreased 16% and a minimal 3% savings 
was realized on the co-payment side. ConClusions: Huge savings were real-
ized with this new reference pricing method, where the financer realized the 
most of the savings.
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objeCtives: Older people (> 70) with high risk of future health problems discharged 
from acute medical units (AMU) within 72 hours, in Nottingham and Leicester, 
England, were included in an RCT of an interface geriatric intervention (IGI) compris-
ing geriatrician assessment and further specialist management. The objective was 
to assess cost-effectiveness of IGI compared to standard care. Methods: In the 
trial-based economic evaluation, 417 participants (IGI: 205) were analysed at 90-day 
follow-up. Health (inpatient, day-case, outpatient), social care and IGI resource-use 
data were collected and combined with unit costs to estimate total cost. Quality-
adjusted life years (QALY), based on EQ-5D valuations at baseline and follow-up, 
were obtained for 254 (60.9%) participants. Multiple imputation by chained equa-
tions was applied to deal with missing QALY values. Cost and QALYs were adjusted 
by baseline characteristics using regression methods, and probabilistic incremental 
cost-effectiveness ratios (ICER) were constructed. Sub-group analysis was carried 
demographic factors underlying the cost of GMS prescribing in Ireland are complex 
and inter-related. Alternative solutions to the question GMS coverage in the elderly 
may need to be found soon that prove fiscally and economically sustainable. The 
large gap in GMS prescribing costs between men and women in early adulthood 
requires further investigation.
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objeCtives: Cost-effectiveness analyses play a key role in the reimbursement of 
health care technologies and require health care resource use (HRU) cost inputs. 
Inaccuracies in inputs can lead to potentially significant differences in results. Thus, 
the availability of HRU costs is vital for decision-making. This study’s objective is to 
assess the transparency and ease of access to HRU costs in France, Germany, Italy, 
Spain and the UK. Methods: A targeted search and contact with country-specific 
representatives highlighted existing national documentation. A cross-sectional 
selection of costs were searched for including GP and nurse costs; hospital bed and 
overhead costs; drug prices; follow-up/out-patient visit costs; and the availability of 
Diagnosis-Related Group (DRG) codes and tariffs. The transparency and availability 
of costs were assessed using the following criteria: the date, access restrictions and 
the need for assumptions to generate cost estimates. Results: DRG tariffs were 
identified for all countries, but the availability of other data varied. Drug prices were 
obtainable online (such as the website MedicPrix, France), but others required paid 
registration (Giofil, Italy). The UK had the most accessible primary and secondary 
care HRU cost data through PSSRU. Italy was the least transparent however AIFA 
informed us a website reform will increase access to data in 2014. Where not explicit, 
HRU costs can be indirectly derived from total procedure codes (for example through 
ATIH, France). Spain and Italy’s regional structure made sourcing national cost data 
challenging, resulting in wide ranges in input costs in published cost-effectiveness 
analyses. ConClusions: Whilst some nations provided transparent HRU cost data, 
others did not, causing inconsistent inputs across cost-effectiveness analyses. To 
minimise inconsistency we propose a hierarchy of evidence for use when sourc-
ing costs: 1) Govt/health service official sources; 2) Official international websites 
(OECD/WHO); 3) Published economic studies; 4) Published non-economic studies; 
5) National expert opinion; and 6) Unofficial websites/sources.
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objeCtives: Standard approaches to economic evaluations based on cost utility 
analysis are increasingly considered inadequate. While simple and intuitive, it is 
acknowledged that the QALY alone does not capture all aspects of health benefit. 
Multi Criteria Decision Analysis (MCDA) has been proposed as a way of incorporat-
ing multiple factors influencing the value of a health technology. The objective of 
this study was to analyse past reimbursement recommendations by the National 
Centre for Pharmacoeconomics (NCPE) in Ireland in order to identify factors which 
have influenced decisions in the past. Methods: Based on published literature, 
national guidelines and experience, a list of potentially influencing criteria was 
identified. Information on each criterion was extracted for each full pharmacoeco-
nomic assessment conducted by the NCPE. Logistic regression was used to estimate 
the impact each of these criteria has had on past recommendations. Model fit was 
assessed using the Deviance Information Criterion and the best fit model was cho-
sen using backwards stepwise regression. Results: Between 2006 and May 2013 the 
NCPE conducted 54 full pharmacoeconomic assessments. Each of these was scored 
against 14 criteria, which can be grouped into clinical utility, consumer demand, 
economic incentives, societal perspective and efficiency/affordability. The model 
of choice identified criteria of each group which impact on reimbursement recom-
mendations. ConClusions: This analysis shows that factors other than cost per 
QALY have impacted on past valuations of health technologies in Ireland. Since the 
analysis was carried out retrospectively, these factors have influenced decisions in 
an informal manner and do not necessary represent the factors which should influ-
ence future reimbursement decisions. This approach contrasts with methods used 
elsewhere to estimate weights for the criteria. The results of this analysis provide 
a basis for the development of a MCDA approach to HTA in Ireland, which has the 
potential to improve consistent and transparent decision making.
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objeCtives: To model the age, gender and regional pattern of GMS coverage rates 
as they are key determinants of public spending on GMS medicines. Methods: 
We used PCRS (Primary Care Reimbursement Service) and CSO (Central Statistics 
Office) databases to estimate GMS coverage rates by age, gender and region in 2010 
and 2011. Assuming log-normally distributed incomes we used CSO SILC data to 
estimate GMS coverage semi-elasticities in 2010. We estimated how much GMS 
male and female coverage rates in 7 adult age categories and 8 Irish regions in 
2010 responded to changing average income levels, income inequality and income 
thresholds. We tracked how well our predicted GMS coverage rates fitted actual 
rates in 2011. We simulated the 2011 GMS medicines cost burden of a ceteris 
paribus repeat of the 2010 changes in income and income-inequality. Results: 
Our modelled coverage rates have high goodness of fit compared to conventional 
econometric estimates. Coverage income-semi-elasticity ranges from .7 to 2.3, is 
highest for elderly age cohorts and in the South-East and South-West regions and 
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data collection is used for the same resource items. Methods: Articles citing 
38 trial-based resource use instruments catalogued in the MRC-funded Database 
of Instruments for Resource Use Measurement (www.DIRUM.org) were identified 
using Google Scholar, ISI Web of Science and Scopus, and screened according to 
resource use measure usage. Data were extracted on: the method of administra-
tion, resources measured, rates of return and the nature of the other methods 
of resource use measurement. Results: A total of 146/1503 citations met the 
screening criteria. Nearly all (143/146) used resource use instruments derived from 
Beecham and Knapp’s Client Service Receipt Inventory. Most instruments relied 
on patient- or proxy-recall (126/146) generally administered during researcher 
interviews. Primary and secondary care usage were the most widely asked items 
(136/146) with 75 using no supplementary supporting data such as from hospital 
notes. Twelve studies compared one or more method of data collection for the 
same resource items with 8 indicating good agreement between medical records 
and patient/carer recall, 1 indicating the greater reliability of case notes and 3 were 
not evaluable. ConClusions: Resource use instruments based on patient recall 
are valuable complements to other methods and essential for certain items (e.g. 
out of pocket costs, non-medical costs). However, there remains inappropriate use 
in circumstances where more objective measures are available.
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objeCtives: Generic drugs provide a safe, effective and affordable alternative to 
medicines whose patent protection has expired. Generics have to meet the same 
quality standards as the innovator drugs; the only substantive difference is the price. 
Generic manufacturers compete ‘on a knife-edge’ of narrow margins of profitability. 
The generic pharmaceutical industry is risky and complex, success depends on the 
number of other generic drug manufacturers on the market, which affects the profit 
margins and volumes that each company could realize. The objective of the current 
study was to develop a model that explains the effect of generic drug entry on price 
competition after patent expiration in the pharmaceutical industry. Methods: 
Innovators and their generics selected from all the chemical entities whose pat-
ents expired from 1999 through 2009. Data were obtained from IMS Health (Market 
Segmentation Report) and National Department of Health (Database of Medicine 
Prices) for the patents’ expiration dates, prices, sales volume, therapeutic group, 
schedule, and dosage forms of drugs in the sample. Results: A year after pat-
ent expiration, the innovators’ products retained an average of 59% of the market 
share; the generic-to-innovator price ratio was at an average of 65%. By the end of 
the first year after patent expiration, an average of 2 generics was registered per 
innovators’ product. ConClusions: Generic entry is commercially driven; it is 
influenced by the market size of the innovator product prior to the expiry of the 
patent protection. Generic penetration is slow, only intensifies after 5 years since 
the loss of patent protection. The price erosion of the innovator product is strongly 
influenced by generic penetration. The cost of drugs in South Africa is not coming 
down fast enough.
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objeCtives: Economic evaluations often ignore the possibility of non-linear 
health care costs when chronic diseases occur in combination. This paper aims 
to quantify the comparative effect of single and multiple chronic diseases on hos-
pital resource use. Methods: Using records of all admissions to public hospitals 
in the state of Victoria, Australia in 2010-2011 we estimate multiple regression 
models of hospital length of stay (and total annual discharges) for combinations 
of 11 chronic diseases. For length of stay we run separate models for same-day 
and overnight stays, adjusting for observed and unobserved characteristics of 
patients. Results: A higher chronic disease count decreases the odds of a same-
day hospitalization (day-case) exponentially while some disease combinations 
increased these odds. Having ischemic heart disease (IHD) & dementia doubled the 
odds of a day-case compared to a patient with dementia only. Among overnight 
stays, having a mental disease had the highest single disease effect on length 
of stay (LOS) – increasing LOS by 3-4 days. Some disease combinations had non-
additive effects (i.e. their combined effect was greater/less than the sum of their 
single disease effects) on LOS while others were additive. The interaction effect in 
a depression-renal failure combination added 3 days to its single disease effects, 
while in cancer-osteoporosis it was -2 days. Disease combinations that produced 
a positive interaction effect were usually unrelated diseases. We found disease 
count to be positively correlated with number of admissions. Having a combina-
tion of diseases was generally found to have a less-than-additive effect on the 
number of admissions. ConClusions: Patients with chronic diseases have a 
resource use pattern that includes longer lengths of stays and more admissions. 
Combinations of unrelated diseases are particularly correlated with longer lengths 
of stay therefore it is the disease and combination type that is associated with 
higher lengths of stay and admitted episodes.
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out for patients who had not been hospitalized within six months prior to index 
AMU admission. Results: In the whole group, total cost for IGI was higher (£207.4, 
95%CI: £94.8-£331.2) with no QALY gain (-0.001, 95%CI: -0.009-0.007); IGI was domi-
nated by standard care (3%-probability of ICER< £30,000/QALY). In the sub-group 
of 209 patients (IGI: 106) without a hospital stay in the previous six months, total 
cost for IGI was lower (-£274.2, 95%CI: -£480.4--£46.3) with non-significant QALY 
gain (0.001, 95%CI: -0.011-0.013), and 49%-probability of IGI being dominant (90%- 
probability of ICER≤ £30,000/QALY). In the whole group (sub-group), inpatient cost 
was lower by £212 (£778), and social care cost was higher (lower) by £220 (£141), 
comparing IGI to standard care. ConClusions: The IGI for high-risk older people 
discharged from AMU was not cost-effective for all patients, but was cost-effective in 
patients without a hospital stay in the previous six months. This suggests targeting 
the intervention is required.
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objeCtives: . To establish the correlation of log mean cost with respect to APACHE 
II score, pre-hospitalization and length of hospital stay, and to determine the intra-
group variance of log mean treatment costs in different parameters. Methods: 
Categorical data was presented as frequencies with percentages and was analyzed 
by Chi-square test, log regression and Pearson correlation. A logarithmic trans-
formation was used for total cost to convert into normal distribution. Geometric 
mean and Geometric SD was used to summarize total cost. One way ANOVA was 
used to compare the mean of log (total cost) across various categorical variables. 
Multiple linear regression was used to find the factors associated with total cost 
of hospitalization of OPP. Correlations was used for measuring the strength of 
linear relationship between total cost and APACHE II score. Results: A significant 
variance in log mean treatment costs was observed in different parameters like 
pseudocholinesterase levels, type of poison consumed, anticholinergics admin-
istered and incidence of intermediate syndrome. A high mean cost was observed 
in patients with a pseudocholinesterase level of less than 2000 and those who 
consumed WHO class Ib pesticide. A cost difference of INR 25,000 was noted in 
patients who developed intermediate syndrome. The APACHE II Score, pre-hos-
pitalization period and length of hospital stay had significant correlation with 
log cost. Among the variables, length of hospitalization had strong correlation 
with log cost (r= 0.673, p< 0.001). For every one-unit increase in pre-hospitalization 
period, APACHE II score and length of hospital stay, the log cost increases by INR 
1.01, 1.27 and 1.5 respectively. ConClusions: High costs of treatment coupled 
with a proportionately great loss of man-days, make OPP an extremely important 
area for pharmacoeconomic evaluation and for framing appropriate policies for 
remedial measures. Hence studies evaluating treatment regimens with respect 
to costs and outcome are highly desirable.
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objeCtives: The demand for intensive care units has risen in the recent years 
as the increasing aged population in all countries and in Turkey. The aim of the 
study is to calculate the average cost of intensive care stay(ICS) and to compare 
the cost with the reimbursement amount depending on a public hospital data 
in Turkey. Methods: The records of ICSed patients from a public hospital in 
Ankara were evaluated retrospectively between November 2011 and January 2012. 
The hospital cost and reimbursement amount were calculated depending on the 
data. Results: A total of 104 patients stayed in the given time line. Four patients 
excluded due to the missing data in files. The average cost of pharmaceuticals, 
medical devices, laboratory, health care and total cost per patient were calculated 
as 1209.16 TL± 492.46, 137.48 TL± 41.08, 422.35 TL± 108.70, 873.10 TL± 247.82 and 
2992.43 TL± 994.06, respectively. The average reimbursement amount per patient 
was calculated as 2846.59 TL± 842.60. The average profit or deficit of the hospital 
were calculated for the 1st,2nd,3rd,4th, 5th,6th, 7th,8th,9-15th,16-29th and 30-51st 
days as 34.90 TL± 49.69, -75.48 TL± 671.39, -23.25 TL± 315.41, 382.80 TL± 368.58, 283.09 
TL± 628.57, -266.13 TL± 612.81, 312.45 TL± 416.11, 118.99 TL± 729.00, -916.58 TL± 
1430.94, -1500.57 TL± 3217.87 and -2054.55 TL± 3204.79, respectively. The profit and 
deficit trend line was calculated with the number of ICS days as “y = -51,889x2 + 
446,98x - 631,73” (y= profit or deficit, x= hospital stay days). ConClusions: It was 
concluded that the average daily cost of ICS increased depending on the length of 
stay. The patients in critical state who needed more ICS days may have caused this. 
On the other hand, it was observed that the fixed daily reimbursement amount is 
inadequate for prolonged ICS. As a result this leads to the deficits of the hospitals 
in the prolonged ICS.
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objeCtives: Instruments for resource use measurement based on patient-recall 
(e.g. questionnaires, logs and diaries) are used extensively in trial-based economic 
evaluations; sometimes on their own and sometimes alongside other methods 
for estimating costs. The aims were to assess: 1) how resource use instruments 
are used in practice; 2) which items of resource use are based most frequently 
on patient-recall; and 3) how estimates compare if more than one method of 
